Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · November 21, 2019

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Atopic Dermatitis

JAMA Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Dermatology
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
JAMA Dermatol 2019 Nov 06;[EPub Ahead of Print], EL Simpson, AS Paller, EC Siegfried, M Boguniewicz, L Sher, MJ Gooderham, LA. Beck, E Guttman-Yassky, D Pariser, A Blauvelt, J Weisman, B Lockshin, T Hultsch, Q Zhang, MA Kamal, JD Davis, B Akinlade, H Staudinger, JD Hamilton, NMH Graham, G Pirozzi, A Gadkari, L Eckert, N Stahl, GD Yancopoulos, M Ruddy, A Bansal

Further Reading